NYMC Faculty Publications

Greater Efficacy With Secukinumab Treatment Is Associated With Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data

Journal Title

Journal of Psoriasis and Psoriatic Arthritis

First Page

73

Last Page

80

Document Type

Article

Publication Date

March 2017

Department

Dermatology

Abstract

Background: Psoriasis negatively affects patients’ quality of life. Secukinumab is a human interleukin-17A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis. Objectives: The current analysis evaluated the benefits of secukinumab by assessing relationships between disease severity and patient-reported symptoms. Methods: Correlations between psoriasis-related itching, pain, and scaling and disease severity scores (Psoriasis Area and Severity Index [PASI] and Investigator’s Global Assessment [IGA]) were evaluated at baseline, Week 12, and change from baseline to Week 12 using secukinumab clinical data from ERASURE and FIXTURE. Symptom responder status and PASI/IGA change were evaluated using logistic modeling. Results: Correlation coefficients ranged 0.11-0.49 for PASI and 0.19-0.52 for IGA. Greater PASI response was related to greater symptom response/complete relief. Conclusions: Results further demonstrate the relationship between traditional clinical measures of disease severity and patient-reported, psoriasisrelated itching, pain, and scaling — hence the need to consider both outcomes together to evaluate treatment effects in this disease fully.

This document is currently not available here.

Share

COinS